These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 9563477

  • 1. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation.
    Fan H, Villegas C, Huang A, Wright JA.
    Cancer Res; 1998 Apr 15; 58(8):1650-3. PubMed ID: 9563477
    [Abstract] [Full Text] [Related]

  • 2. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential.
    Fan H, Villegas C, Wright JA.
    Proc Natl Acad Sci U S A; 1996 Nov 26; 93(24):14036-40. PubMed ID: 8943056
    [Abstract] [Full Text] [Related]

  • 3. Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs.
    Fan H, Villegas C, Huang A, Wright JA.
    Cancer Res; 1996 Oct 01; 56(19):4366-9. PubMed ID: 8813126
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA, Cox AD.
    Oncogene; 2000 Sep 28; 19(41):4685-94. PubMed ID: 11032018
    [Abstract] [Full Text] [Related]

  • 6. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
    Bazarov AV, Adachi S, Li SF, Mateyak MK, Wei S, Sedivy JM.
    Cancer Res; 2001 Feb 01; 61(3):1178-86. PubMed ID: 11221849
    [Abstract] [Full Text] [Related]

  • 7. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.
    Huang A, Fan H, Taylor WR, Wright JA.
    Cancer Res; 1997 Nov 01; 57(21):4876-81. PubMed ID: 9354452
    [Abstract] [Full Text] [Related]

  • 8. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
    Shantz LM, Pegg AE.
    Cancer Res; 1998 Jul 01; 58(13):2748-53. PubMed ID: 9661886
    [Abstract] [Full Text] [Related]

  • 9. Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review).
    Burton TR, Kashour T, Wright JA, Amara FM.
    Int J Oncol; 2003 Jan 01; 22(1):21-31. PubMed ID: 12469181
    [Abstract] [Full Text] [Related]

  • 10. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation.
    Heinicke T, Radziwill G, Nawrath M, Rommel C, Pavlovic J, Moelling K.
    Cancer Gene Ther; 2000 May 01; 7(5):697-706. PubMed ID: 10830717
    [Abstract] [Full Text] [Related]

  • 11. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J, Jiang B, Coffey RJ, Barnard J.
    Mol Cancer Res; 2004 Apr 01; 2(4):233-41. PubMed ID: 15140945
    [Abstract] [Full Text] [Related]

  • 12. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells.
    Ulkü AS, Schäfer R, Der CJ.
    Mol Cancer Res; 2003 Dec 01; 1(14):1077-88. PubMed ID: 14707291
    [Abstract] [Full Text] [Related]

  • 13. The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments.
    Fan H, Huang A, Villegas C, Wright JA.
    Proc Natl Acad Sci U S A; 1997 Nov 25; 94(24):13181-6. PubMed ID: 9371820
    [Abstract] [Full Text] [Related]

  • 14. Resistance of NIH3T3 cells to v-fes transformation induced by a dominant negative H-ras mutant.
    Ogiso Y, Yokoyama T, Watari H, Shih TY, Kuzumaki N.
    Exp Cell Res; 1993 Oct 25; 208(2):415-21. PubMed ID: 7690710
    [Abstract] [Full Text] [Related]

  • 15. While E1A can facilitate epithelial cell transformation by several dominant oncogenes, the C-terminus seems only to regulate rac and cdc42 function, but in both epithelial and fibroblastic cells.
    Fischer RS, Quinlan MP.
    Virology; 2000 Apr 10; 269(2):404-19. PubMed ID: 10753719
    [Abstract] [Full Text] [Related]

  • 16. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation.
    Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP.
    Toxicol Appl Pharmacol; 2001 Sep 15; 175(3):260-8. PubMed ID: 11559025
    [Abstract] [Full Text] [Related]

  • 17. Antigens expressed on NIH 3T3 cells following transformation with DNA from human pancreatic tumor.
    Hollingsworth MA, Rebellato LM, Moore JW, Finn OJ, Metzgar RS.
    Cancer Res; 1986 May 15; 46(5):2482-7. PubMed ID: 3697988
    [Abstract] [Full Text] [Related]

  • 18. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling.
    Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R.
    Oncogene; 2000 Nov 16; 19(48):5419-27. PubMed ID: 11114718
    [Abstract] [Full Text] [Related]

  • 19. Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells.
    Hayes CS, DeFeo K, Lan L, Paul B, Sell C, Gilmour SK.
    Oncogene; 2006 Mar 09; 25(10):1543-53. PubMed ID: 16278677
    [Abstract] [Full Text] [Related]

  • 20. ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf.
    Mercer K, Chiloeches A, Hüser M, Kiernan M, Marais R, Pritchard C.
    Oncogene; 2002 Jan 17; 21(3):347-55. PubMed ID: 11821947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.